191 related articles for article (PubMed ID: 10115803)
1. Biotech drugs: high costs becoming hard to swallow.
Wagner M
Mod Healthc; 1992 Jan; 22(2):24-5, 28-9. PubMed ID: 10115803
[TBL] [Abstract][Full Text] [Related]
2. Biotechnology drugs create new maze of concerns for hospitals.
Lumsdon K
Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
[TBL] [Abstract][Full Text] [Related]
3. Projecting future drug expenditures--1994.
Santell JP
Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
[TBL] [Abstract][Full Text] [Related]
4. The emerging market dynamics of targeted therapeutics.
Calfee JE; Dupré E
Health Aff (Millwood); 2006; 25(5):1302-8. PubMed ID: 16966726
[TBL] [Abstract][Full Text] [Related]
5. Which bottom line?
Shane R
Am J Hosp Pharm; 1991 Oct; 48(10):2130. PubMed ID: 1781465
[No Abstract] [Full Text] [Related]
6. Projecting future drug expenditures--1993.
Santell JP
Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
[TBL] [Abstract][Full Text] [Related]
7. Shades of gray. Secondary drug distributors raise questions.
Lee J
Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
[No Abstract] [Full Text] [Related]
8. Marketplace. How drug company mergers affect HMOs and hospitals.
Moskowitz DB
Faulkner Grays Med Health; 1997 Jun; 51(23):suppl 2 p.. PubMed ID: 10167794
[No Abstract] [Full Text] [Related]
9. Drug Price Index declines as prices weaken for older drugs.
Hosp Mater Manage; 1986 May; 11(5):21-2. PubMed ID: 10277138
[No Abstract] [Full Text] [Related]
10. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
Becker C
Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
[TBL] [Abstract][Full Text] [Related]
11. Competition of high-priced new drugs holds down prices of older drugs.
Hosp Purch Manage; 1982 May; 7(5):14-5. PubMed ID: 10255154
[No Abstract] [Full Text] [Related]
12. Prescription costs become harder to swallow. Providers and payers get a big dose of reality with explosive spending and patient demand for new drugs.
Hensley S
Mod Healthc; 1999 Aug; 29(34):30-4. PubMed ID: 10557476
[TBL] [Abstract][Full Text] [Related]
13. Market access for biopharmaceuticals: new challenges.
Simon F
Health Aff (Millwood); 2006; 25(5):1363-70. PubMed ID: 16966734
[TBL] [Abstract][Full Text] [Related]
14. Slowing rate of cost increases in the pharmacy.
Roark M
Hospitals; 1993 Jan; 67(2):56. PubMed ID: 8419282
[TBL] [Abstract][Full Text] [Related]
15. Generic pharmaceutical prices continue their decline in prices from last year.
Hosp Mater Manage; 1996 Feb; 21(2):1, 12-3. PubMed ID: 10154299
[No Abstract] [Full Text] [Related]
16. Leading 1994 dollar volume pharmaceuticals.
Ramspacher S
Hosp Pharm; 1995 Aug; 30(8):666-9, 673. PubMed ID: 10144644
[No Abstract] [Full Text] [Related]
17. Plans struggle for control of specialty pharma costs.
Carroll J
Manag Care; 2005 Sep; 14(9):41-2, 45-8. PubMed ID: 16238258
[No Abstract] [Full Text] [Related]
18. A commentary on high-cost drugs.
de Leon RF
Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277
[TBL] [Abstract][Full Text] [Related]
19. As biotech turns 20..
Miller HI
Nat Rev Drug Discov; 2002 Dec; 1(12):1007-8. PubMed ID: 12461522
[TBL] [Abstract][Full Text] [Related]
20. Improving the process of medication budget forecasting.
Vermeulen LC; Marnocha RM; Thielke TS
Pharm Pract Manag Q; 1998 Apr; 18(1):72-80. PubMed ID: 10177544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
